Recent Developments In March 2025, Novo Nordisk signed a deal worth up to $2 billion for the rights to UBT251, a new obesity and diabetes drug developed by United BioTechnology
Developed by Gut Health, UAB, and distributed by Gut Health LLC, this supplement is on a mission to make your trips to the bathroom as regular as clockwork
The double-blind RCT STOP KNEE-OA (NCT06191848) has also been planned to compare the efficacy of tirzepatide vs
Additionally, an ongoing clinical study known as the FETR-ALS trial (a phase II randomized controlled trial) has reported that around 40% of participants experienced a slowing or stabilization of their disease following FMT
Epithalon Peptide and Anti-Mutagenic Action In this 2011 study,(8), three different mouse models were used to determine the action of the peptide on chromosomal aberrations
Reference: Tirzepatide-Induced Rapid Weight Loss-Related Thyrotoxicosis - ( Source-Medindia